Amicus Therapeutics

Amicus Therapeutics

Amicus Therapeutics was founded in 2005 by John F. Crowley, known for his family's experience with Pompe disease. The company went public on NASDAQ in 2007 (ticker: FOLD) and has since focused on therapies for rare genetic diseases. The company's strategy centers on developing enzyme-replacement and small-molecule therapies for lysosomal storage disorders, including Pompe disease, Fabry disease, and other rare conditions. Key approved products include Galafold (migalastat) for Fabry disease and a clinical-stage Pompe pipeline. Amicus has also partnered with major biopharma firms for manufacturing and distribution. The firm employs over 1,000 professionals globally, with headquarters in Philadelphia and additional offices in the UK, Europe, and Japan. A philanthropic foundation, the Amicus Therapeutics Foundation, supports patient advocacy and education. In 2021, the company completed an FDA approval for Galafold for young children (per FDA, 2021), expanding the addressable market. Structurally, Amicus Therapeutics operates as a publicly traded biotechnology company, not a family office. The Crowley family maintains significant ownership through shares, but the firm is governed by a corporate board of directors. The business model is pure commercial biotech — drug development and sales — not investment management for external capital.